Cargando…

Survival Outcomes and Prognostic Analysis Following Greater Cytoreductive Radiotherapy in Patients With Metastatic Prostate Cancer

Purpose: To assess the survival outcomes of patients with metastatic prostate cancer (mPCa) who undergo greater cytoreductive radiotherapy in a real-world clinical practice and determine their prognostic factors. Methods: We performed a retrospective study of 160 patients with mPCa who underwent cyt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zitong, Wei, Min, Mai, Lixin, Li, Yonghong, Wu, Jianhua, Huang, Hong, Huang, Sijuan, Lin, Maosheng, Jiang, Xiaobo, Zhou, Fangjian, Liu, Mengzhong, Liu, Yang, He, Liru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555263/ https://www.ncbi.nlm.nih.gov/pubmed/33102216 http://dx.doi.org/10.3389/fonc.2020.549220

Ejemplares similares

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience
por: Liu, Yang, et al.
Publicado: (2021)

Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy
por: Liu, Yang, et al.
Publicado: (2021)

Dose-volume analysis of predictors for acute anal toxicity after radiotherapy in prostate cancer patients
por: Peng, Xingsi, et al.
Publicado: (2019)

Successful management of prostate cancer with bulky pelvic lymph node metastases after rapid development of castration-resistant prostate cancer: a case report with review of the literature
por: Mai, Lixin, et al.
Publicado: (2020)

Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors
por: He, Liru, et al.
Publicado: (2020)

Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma
por: Liu, Yang, et al.
Publicado: (2021)

Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma
por: Liu, Yang, et al.
Publicado: (2021)

Molecular Characterization and Clinical Relevance of N(6)-Methyladenosine Regulators in Metastatic Prostate Cancer
por: Liu, Qiwei, et al.
Publicado: (2022)

Analyses of the factors influencing the accuracy of three-dimensional ultrasound in comparison with cone-beam CT in image-guided radiotherapy for prostate cancer with or without pelvic lymph node irradiation
por: Zhou, Sha, et al.
Publicado: (2019)

Cytoreductive surgery for men with metastatic prostate cancer
por: Katelaris, Nikolas, et al.
Publicado: (2016)

Impact of tumor cytoreduction in metastatic prostate cancer
por: Sow, Yaya, et al.
Publicado: (2019)

Survival in Patients With Metastatic Prostate Cancer Undergoing Radiotherapy: The Importance of Prostate-Specific Antigen-Based Stratification
por: Tian, Zijian, et al.
Publicado: (2021)

Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response
por: Klusa, Daria, et al.
Publicado: (2021)

Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer
por: Ollivier, Luc, et al.
Publicado: (2021)

Treatment results of radiotherapy to both the prostate and metastatic sites in patients with bone metastatic prostate cancer
por: Inaba, Koji, et al.
Publicado: (2021)

Spontaneous regression of metastatic renal cell carcinoma after cytoreductive nephrectomy: A case report
por: Muraoka, Kuniyasu, et al.
Publicado: (2020)

A rapid progression of new metastatic lesion after cytoreductive nephrectomy: A case report
por: Steven, Steven, et al.
Publicado: (2021)

Plan quality and treatment efficiency assurance of two VMAT optimization for cervical cancer radiotherapy
por: Huang, Sijuan, et al.
Publicado: (2023)

Development and internal validation of a novel nomogram for predicting lymph node invasion for prostate cancer patients undergoing extended pelvic lymph node dissection
por: Li, Zhen, et al.
Publicado: (2023)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?
por: Adashek, Jacob J., et al.
Publicado: (2021)

AB056. Cytoreductive radical prostatectomy for men with oligo-metastatic prostate cancer
por: Liu, Shengjie, et al.
Publicado: (2017)

Achieving Intraperitoneal Disease Control Using Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Two Cases of Metastatic Breast Cancer
por: Barakat, Philipp, et al.
Publicado: (2023)

Establishment and validation of a nomogram to select patients with metastatic sarcomatoid renal cell carcinoma suitable for cytoreductive radical nephrectomy
por: Zhou, Yulin, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status
por: Liu, Guoqiang, et al.
Publicado: (2021)

The Yin and Yang of Cytoreductive SBRT in Oligometastases and Beyond
por: Onderdonk, Benjamin E., et al.
Publicado: (2019)

Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner
por: Li, Qiaoqiao, et al.
Publicado: (2012)

Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer
por: Gaudreault, Mathieu, et al.
Publicado: (2023)

A retrospective analysis for investigating the relationship between FIGO stage IVA/IVB and cytoreductive surgery with prognosis in epithelial ovarian cancer
por: Liu, Hong, et al.
Publicado: (2023)

An Updated Systematic and Comprehensive Review of Cytoreductive Prostatectomy for Metastatic Prostate Cancer
por: Yanagisawa, Takafumi, et al.
Publicado: (2023)

Predicting incomplete cytoreduction in patients with advanced ovarian cancer
por: Egger, Eva K., et al.
Publicado: (2022)

Radiotherapy plus immune checkpoint inhibitor in prostate cancer
por: Li, Tianjie, et al.
Publicado: (2023)

Selection of Optimal Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Clear Cell Renal Cell Carcinoma: A Predictive Model Based on SEER Database
por: Zhang, Yishan, et al.
Publicado: (2022)

Clinical Significance of Mesenchymal Circulating Tumor Cells in Patients With Oligometastatic Hormone-Sensitive Prostate Cancer Who Underwent Cytoreductive Radical Prostatectomy
por: Yang, Guanjie, et al.
Publicado: (2022)

The current role of secondary cytoreductive surgery for recurrent ovarian cancer
por: de Bree, Eelco, et al.
Publicado: (2022)

Temperature management during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
por: Ramirez, Maria F., et al.
Publicado: (2023)

Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome
por: Riva, Giulia, et al.
Publicado: (2017)

A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer
por: Zhou, Jianyuan, et al.
Publicado: (2021)

Big Data Analytics for Prostate Radiotherapy
por: Coates, James, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_up6uhtncrqecmkrp95e7le1bsn